Norepinephrine: Nursing Drug Guide, Extravasation Risk & NCLEX Review

U.S. labeling describes Norepinephrine Bitartrate Injection, USP—typically supplied as 4 mg/4 mL (1 mg/mL) base in single-dose amber vials for IV infusion after dilution. Concentrate and premixed presentations vary by manufacturer; always match the vial strength to pharmacy dilution and pump programming.

Do not confuse norepinephrine bags or vials with epinephrine, dopamine, or dobutamine drips in the medication room or on the pump library.

Per FDA prescribing information, norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with severe, acute hypotension—common ICU and emergency contexts such as sepsis with persistent hypotension after fluids, or low-output states associated with heart failure.

↔On a small screen, swipe or scroll sideways to see the full table.

Norepinephrine is a catecholamine sympathomimetic with strong alpha-adrenergic vasoconstriction and beta-1 inotropic effects. At the bedside, nurses track mcg/min because the labeled initial rate is 8–12 mcg/min with typical maintenance 2–4 mcg/min after hemodynamic response—not weight-based mcg/kg/min like dopamine.

Pressor action begins rapidly and reaches steady state within about 5 minutes; effects terminate within 1–2 minutes after the infusion stops because of neuronal uptake and metabolism (COMT/MAO). Reflex vagal slowing can produce bradycardia despite rising blood pressure—do not assume the patient is improving solely from the heart rate.

Individualize to hemodynamic targets. Use an infusion pump in an intensive care setting when possible. All doses below refer to norepinephrine base in mcg/min per reviewed labeling.

BP monitoring during titration

Labeling directs monitoring blood pressure every two minutes until the desired hemodynamic effect is achieved, then every five minutes for the duration of the infusion.

MAO inhibitor / tricyclic antidepressant patients

If norepinephrine cannot be avoided in patients who recently received MAO inhibitors (including linezolid) or tricyclic antidepressants, monitor closely for severe, prolonged hypertension per labeling—not specified as a fractional starting dose reduction in the reviewed prescribing information.

Pediatrics: Safety and effectiveness in pediatric patients have not been established per labeling.

Missed dose: Not applicable to continuous infusion—if interrupted, verify line patency, compatibility, and prescriber direction before restarting; taper when discontinuing.

Pretreatment checks

• Confirm hypovolemia is being treated—fluids and source control before vasopressors when shock is hypovolemic
• Perform medication reconciliation for MAO inhibitors (including linezolid), tricyclic antidepressants (e.g., amitriptyline), halogenated anesthetics, and concurrent vasopressors
• Verify pharmacy dilution and concentration; program pump in mcg/min with independent double-check (not mg/hour alone)
• Establish large-vein access—prefer central line when ordered; follow central line care and assess the site frequently
• Attach cardiac monitoring; document baseline blood pressure, heart rate, rhythm, and urine output
• Inspect solution—colorless; do not use if pinkish, darker than slightly yellow, or precipitated per labeling
• Screen for sulfite sensitivity (sodium metabisulfite) and history of asthma

Contraindications

• None listed in the reviewed prescribing information

Warnings (labeling)

• Tissue ischemia: Hypovolemic patients may develop severe vasoconstriction, poor renal perfusion, and lactic acidosis despite normal BP—correct volume first
• Avoid in mesenteric or peripheral vascular thrombosis—may extend infarction
• Extravasation: Necrosis—infuse into large vein; avoid leg veins in elderly or occlusive vascular disease; avoid catheter-tie-in technique
• Arrhythmias: Monitor continuously, especially with hypoxia, hypercarbia, or halogenated anesthetics
• Abrupt stop: Marked hypotension—taper rate while expanding intravascular volume
• Sulfite excipient: May cause anaphylaxis or bronchospasm in susceptible patients

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Incompatibilities: Avoid contact with iron salts, alkalis, or oxidizing agents. Do not administer whole blood or plasma through the same infusion set.

Route: Intravenous continuous infusion only. Dilute before use—add contents of one 4 mg/4 mL vial to 1000 mL of 5% dextrose or dextrose-containing saline (standard 4 mcg/mL). Dextrose reduces oxidation loss per labeling. Higher concentrations may be used when fluid restriction is required per pharmacy protocol.

• Infuse through a large vein; avoid leg veins in elderly patients or those with occlusive vascular disease of the legs
• Use IV infusion pump setup programmed in mcg/min with verified mL/hour after concentration check
• Check infusion site frequently for free flow, swelling, coolness, blanching, or pain
• Keep phentolamine and extravasation protocol supplies available
• Store diluted solution up to 24 hours at room temperature, protected from light per labeling

• Improved mean arterial pressure and perfusion after appropriate volume resuscitation
• Urine output and mental status improve when renal and cerebral perfusion recover
• Heart rate may remain slow or normal because of reflex vagal activity—assess perfusion, not rate alone
• Lactate and clinical perfusion trend improve when shock is resolving—reassess if lactate rises despite acceptable BP

Escalate immediately for extravasation, ischemia, or life-threatening rhythm or pressure changes.

• Extravasation, blanching, coolness, or severe pain at the IV site—stop infusion and initiate phentolamine infiltration per labeling
• New sustained ventricular palpitations or wide-complex tachycardia on monitor
• Gangrene, mottling, or absent distal pulses—especially with occlusive vascular disease or prolonged high-dose infusion
• Oliguria and rising lactate despite acceptable blood pressure—suspect occult hypovolemia or visceral ischemia
• Severe headache, chest pain, or neurologic change with hypertension—possible excessive vasopressor effect or overdose

Labeling states the most common adverse reactions are hypertension and bradycardia. Highlights also list ischemic injury, anxiety, transient headache, respiratory difficulty, and extravasation necrosis at the injection site.

↔On a small screen, swipe or scroll sideways to see the full table.

Overdosage per labeling may cause headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output. Discontinue norepinephrine until the patient stabilizes.

Management (labeling)

• Stop or reduce infusion rate until adverse effects resolve
• Monitor blood pressure, rhythm, and perfusion until stable
• No specific systemic reversal agent listed in reviewed prescribing information

Extravasation antidote: Phentolamine mesylate infiltration—adults: 5–10 mg in 10–15 mL 0.9% sodium chloride as soon as possible; sympathetic blockade causes local hyperemia if infiltrated within 12 hours per labeling.

Systemic antidote: Not specified in the reviewed prescribing information beyond discontinuation and supportive care.

• Norepinephrine vs epinephrine vs dopamine vs dobutamine—triple-check MAR, vial/bag label, and pump library; dosing units differ (mcg/min vs mcg/kg/min)
• NE / noradrenaline / Levophed verbal orders—require read-back with concentration and mcg/min rate
• mcg/min vs mg/hour vs mL/hour—independent double-check every new bag and rate change
• Undiluted vial (1 mg/mL) vs diluted bag (4 mcg/mL)—never connect concentrate directly to patient
• Discolored solution—pinkish or darker than slightly yellow means do not administer
• Peripheral vs central access—extravasation risk is highest peripherally; label line and handoff access type

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous cardiac rhythm and frequent blood pressure (q2 min during titration, q5 min during maintenance per labeling)
• Urine output, capillary refill, and extremity perfusion
• IV site every 1–2 hours (or per ICU protocol) for extravasation
• Serial lactate and renal/electrolyte trends during shock
• Blood glucose when patient receives antidiabetic therapy
• Signs of arrhythmia, pulmonary edema, or ischemic pain

Document

• Starting concentration, mcg/min rate, mL/hour, and response after each titration
• Volume resuscitation given before and during pressor therapy
• IV access type (central vs peripheral) and site condition
• Patient education on immobilizing the line and reporting pain, burning, or numbness at the site

• This medicine is given continuously through an IV to support blood pressure during severe illness—do not adjust the pump or pull on the tubing
• Report immediately any burning, pain, numbness, coolness, or swelling near the IV site—extravasation can damage tissue
• Expect frequent blood pressure checks and monitoring alarms while the infusion runs
• The drip will be slowed gradually—not stopped suddenly—to prevent a dangerous blood pressure drop
• Family should know this is a high-alert ICU medication used when the care team is treating shock or severe hypotension

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for norepinephrine using a tabbed ICU case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, perfusion trend interpretation, matrix urgency sorting, MAO-inhibitor judgment, and phentolamine cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.